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To enable an up-to-date molecular analysis of human 
immunodeficiency virus (HIV) genotypes circulating in 
Germany we have established a surveillance system 
based on recently acquired HIV infections. New HIV 
infections are reported to the Robert Koch Institute 
as a statutory duty for anonymous notification. In 
2013 and 2014, a dried serum spot (DSS) sample was 
received from 6,371 newly diagnosed HIV-cases; their 
analysis suggested that 1,797 samples originated 
from a recent infection. Of these, 809 were success-
fully genotyped in the pol region to identify transmit-
ted drug resistance (TDR) mutations and to determine 
the HIV-1 subtype. Total TDR was 10.8%, comprising 
4.3% with mono-resistance to nucleoside reverse tran-
scriptase inhibitors (NRTIs), 2.6% to non-NRTIs, 3.0% 
to protease inhibitors and 0.6% and 0.2%, respec-
tively, with dual- and triple-class resistances. HIV-1 
subtype B was most prevalent with 77.0%. Non-B 
infections were identified more often in men and 
women with heterosexual transmission compared with 
intravenous drug users or men who have sex with men 
(79% and 76%, 33%, 12%; all p < 0.05). Non-B subtypes 
were also more frequently found in patients originat-
ing from countries other than Germany (46% vs 14%; 
p < 0.05) and in patients infected outside of Germany 
(63% vs 14%; p < 0.05).
Introduction
Continuous molecular HIV surveillance provides valu-
able public health information concerning the trans-
mission of drug-resistant viruses and the dynamics of 
currently circulating variants. Transmitted drug resist-
ance (TDR) has significant clinical consequences as 
it is associated with an increase in the failure rate of 
antiretroviral therapy (ART) [1]. With prevalence of TDR 
(at least one resistance mutation) ranging between 
10% and 15% in several European countries and in 
North America [2-6], the problem is of substantial con-
cern. Genotypic resistance testing is therefore recom-
mended before commencing first-line treatment [7]. 
The prevalence of TDR in a country is determined by 
the history of clinical therapy regimens and the failures 
resulting from resistance. TDR can vary depending on 
transmission route, country of origin of the patient and 
country of infection [6]. From a virological perspective, 
TDR is largely determined by the persistence of the 
associated mutation(s). Persistence of those mutations 
depends mainly on the fitness costs to the virus and on 
the viral genetic background (e.g. chance of compensa-
tory mutations) [8].
Knowledge of currently circulating HIV subtypes in a 
country and the dynamics of their spread is of epidemi-
ological and clinical relevance. This information affects 
the safety and accuracy of HIV diagnostics and is valu-
able for HIV prevention and vaccine development.
The objective of this study was to determine TDR and 
HIV-1 subtypes in a substantial subset of new HIV-1 
infections diagnosed in 2013 and 2014 in Germany. We 
intended to examine transmissions from a restricted 
period of time and therefore, only recently acquired 
infections among the newly diagnosed cases were 
included. We aimed to analyse TDR and transmitted 
HIV-1 subtypes in the main transmission groups: men 
who have sex with men (MSM), persons with het-
erosexual contact (HET) and people who inject drugs 
(PWID), considering sex and origin of the infected indi-
vidual and place of infection. 
Methods
Clinical samples
The data protection officer of the RKI and the German 
Federal Commissioner for Data Protection and 
Freedom of Information approved the study protocol 
(III-401/008#0016).
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RNA isolation and HIV sequencing
HIV RNA from 4 x 100 µL DSS was extracted accord-
ing to the manufacturer’s instructions with the 
manual NucliSense Magnetic Extraction method for 
samples collected in 2013 or the automated Biomerieux 
EasyMag platform for samples collected in 2014 (both 
bioMerieux, Capronne, France). Viral RNA was quanti-
fied using an in house LTR RT-TaqMan PCR according 
to a modified protocol [9]. As concentration controls, 
serial dilutions of the IIIB strain of HIV-1 in human 
HIV-negative plasma was dropped onto filter cards 
(DPS standard). Samples were analysed using a newly 
designed HIV-1 group M generic RT-PCR system (in 
house pol RT-PCR) covering the genomic region of HIV-1 
protease (AS9–99) and reverse transcriptase (AS1–
252) including all resistance-associated positions. The 
in house pol RT-PCR assay consists of two pol RT-PCRs 
yielding two overlapping amplicons: a fragment 1 of 
576 bp (primer_A: CCCTCARATCACTCTTTggCARCgA, 
position 2,252–2,276; Primer_B: 
CCTAATTgAACYTCCCARAARTCYTgAgT, position 2,799–
2,827) and a second fragment 2 of 718 bp (Primer_C: 
AAACAATggCCATTRACAgARgA, position 2,613–2,636; 
primer_D: CTAAYTTYTgTATRTCATTgACAgTCCA, posi-
tion 3,303–3,330). All nucleotide positions refer to 
sequence of the HXB2 genome (accession number 
K03455). The detection limit of the in house pol RT-PCR 
was shown to be equivalent to 1,000 copies/mL DPS 
standard (highest dilution resulting in 100% posi-
tive PCR outcome). Population-based sequencing was 
performed and a consensus sequence from both frag-
ments was obtained.
HIV-1 subtyping
The HIV-1 subtype was assigned by applying the REGA 
HIV-1 subtyping tool (REGA HIV Subtyping Tool Version 
Figure 1
Prevalence of transmitted drug resistance mutations by drug class (A) and predicted susceptibility to antiretroviral drugs by 
level of resistance (B) in the study population, Germany, 2013–14 (n = 809)
B. Susceptibility by resistance level
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NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitor.
Panel B: Prediction according to Stanford SIR algorithm: intermediate levels of resistance (light colours) and high levels of resistance (dark 
colours); low and potentially low levels are not indicated.
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3.0) and COMET HIV-1 (Version 1.0) [10] to the pol 
sequence. Only subtype classifications based on boot-
strap values of > 70% in the tree topology were taken 
into account. In cases where a subtype or circulating 
recombinant form (CRF) was not assigned by either 
subtyping tool, the strain was classified as unique 
recombinant form (URF). In addition, a distance-based 
neighbour-joining method and bootstrap (PHYLIP ver-
sion 3.6) was calculated using an extended panel of 
subtype reference sequences from the Los Alamos HIV 
sequence database.
HIV drug resistance interpretation and 
calculation of the prevalence of transmitted 
drug resistance
The World Health Organization (WHO)’s surveillance 
drug resistance mutations (SDRM) list was used to 
interpret TDR [11]. Levels of expected resistance to 
each of the three drug classes nucleoside reverse tran-
scriptase inhibitors (NRTI), non-nucleoside reverse 
transcriptase inhibitors (NNRTI) and protease inhibi-
tors (PI) as mono, dual or triple class resistance were 
predicted using the Stanford algorithm (version 7.0). 
Three levels of resistance were scored: high (R), inter-
mediate (I, intermediate and low), sensitive (S, poten-
tially resistant and sensitive).
Statistical analysis
Descriptive statistics for continuous variables were 
calculated as medians and interquartile ranges (IQR). 
Differences in proportions, odds ratios (OR) and 95% 
confidence intervals (CI) were assessed by two-sided 
Fisher’s exact test using EPICALC 2000 software (ver-
sion 1.02; Gilman and Myatt 1997). A two-sided p 
value ≤ 0.05 was considered significant.
Results
Characterisation of the study population
In 2013 and 2014, a total of 6,371 DSS prepared from 
residual serum of newly HIV-diagnosed cases were 
submitted to the RKI along with the anonymous report. 
Of these, 2,034 (32%) were serologically classified as 
recent HIV infections using the BED-CEIA. The viral load 
was reported for 700 and a CD4+ T-cell count for 543 
of the 2,034 specimens. Specimens with CD4+ T-cell 
counts < 200 cells/µL (n = 108) or viral loads < 400 cop-
ies/mL (n = 50) or both (n=8) were reclassified as ‘long-
standing infections’ and, together with repeatedly 
reported cases (n = 71), excluded, resulting in 1,797 
DSS. Sufficient material (four serum spots à 100 µL) 
was available for 1,387 of those specimens. The pol 
RT-PCR amplification and sequencing was successful in 
809 samples; these represented the final study panel 
of recent HIV infections. A viral load was reported for 
298 of 809 cases, with a median of 184,481 copies/mL 
(IQR: 45,405–983,158). Among these 298 cases, CD4+ 
T-cell counts were available for 214, with a median 
of 357 cells/µL (IQR: 278–487). The proportional dis-
tribution of recently infected cases analysed by sex, 
transmission routes, country of origin and country of 
Figure 2
Subtype distribution (A) in the main transmission groups 
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HET: persons with heterosexual contact; HET_f: female persons 
with heterosexual contact; HET_m: male persons with 
heterosexual contact; MSM: men who have sex with men; PWID: 
people who inject drugs.
a Transmission group `other´(n=6, see Table 1) was excluded from 
the data set.
b Patients from the Middle East, North and sub-Saharan Africa.
c Patients from North and Latin America.
d Patients from South and South-east Asia.
e Two patients from the Caribbean, one patient from Oceania and 
two patients with unknown non-German origin were excluded.
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infection extracted from sociodemographic data sub-
mitted with the notification form are shown in Table 1.
Prevalence of transmitted drug resistance
The overall prevalence of TDR in patients with recently 
acquired HIV infection diagnosed in 2013 and 2014 was 
10.8% (n = 87/809; 95% CI: 8.8–13.1). This comprised 
mono-resistance to NRTIs in 4.3% (35/809; 95% CI: 
3.1–6.0) of the patients, to NNRTIs in 2.6% (21/809; 
95% CI: 1.7–4.0) and to PIs in 3.0% (24/809; 95% CI: 
2.0–4.5) of cases. Dual and triple class resistance was 
identified in 0.6% (n = 4 NRTI/NNRTI; n = 1 NNRTI/PI) 
and 0.2% (n = 2 NRTI/NNRTI/PI) of the patients, respec-
tively (Table 2).
Of all 52 NRTI-associated mutations identified, 46 were 
thymidine analogue mutations (TAM), namely: the 
revertants of T215Y (T215CDEISV; 2.3%; 19/809), M41L 
(2.2%; 15/809), K219ENQR (0.9%; 7/809) and D67EGN 
(0.6%; 5/809). TAM were selected by the thymidine 
analogues and conferred intermediate resistance to 
azidothymidine (AZT) and stavudine (D4T). The most 
prevalent NNRTI resistance mutations were K103N and 
K103S (2.5%; 20/809), selected by first generation 
NNRTIs. The PI-selected resistance mutations M46I and 
M46L were present at a level of 1.6% (13/809) associ-
ated with resistance to a broad spectrum of PIs: ataza-
navir/ritonavir (ATV/r), fosamprenavir (FPV/r), indinavir 
(IDV/r), lopinavir (LPV/r), nelfinapir (NFV) and triprana-
vir (TPV/r). The PI-selected resistance mutations L90M 
(resistance to LPV/r, ATV/r, saquinavir (SQV)/r, IDV/r, 
NFV) and V82ACFLTMS (resistance to FPV/r, TPV/r, 
IDV/r, LPV/r, ATV/r) were present at levels of 0.7% 
(6/809) and 0.9% (7/809), respectively (Figure 1A and 
B).
Drug resistance mutations observed in transmitted HIV 
strains mainly induced intermediate levels of resistance 
to NRTI and PI (mainly resistance-associated singleton 
mutations). High levels of resistance were frequently 
observed to the NNRTIs efavirenz (EFV) and nevirap-
ine (NVP) and were caused primarily by the prevalent 
resistance mutation K103N (Figure 1B).
We found no correlation between TDR and sex, trans-
mission group, origin of patient or country of infection 
in general or for any resistance class (all p values > 0.05) 
(Table 2).
Prevalence of HIV-1 subtypes
The most prevalent HIV-1 subtype in the total study 
population (n = 809) was subtype B with 77.0% 
(623/809; 95% CI: 73.9–79.8), while 23.0% of HIV-1 
infections (186/809; 95% CI: 20.2–26.1) were caused 
by non-B subtypes including A (5.1%, 41/809), C 
(3.6%, 29/809), D (0.7%, 6/809), F (1.6%, 13/809), G 
(2.7%, 22/809), CRF01_AE (2.0%, 16/809) and CRF02_
AG (3.3%, 27/809) as well as 4.0% (32/809) other rare 
CRFs (06_cpx, 07_BC, 12_BF, 18_cpx, 19_cpx, 34_01B, 
35_AD, 44_BF, 49_cpx) and URFs. These rare CRFs 
Figure 3
Prevalence of HIV-1 subtypes stratified by (A) main 
transmission groups and (B) origin of patient, Germany 
2013–14 (n = 809)
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HET: persons with heterosexual contact; MSM: men who have sex 
with men; PWID: people who inject drugs.
a Transmission group `other´(n=6), see Table 1.
b Patients from South and South-east Asia.
c Patients from North and Latin America.
d Patients from Middle East, North and sub-Sahara Africa.
e Two patients from the Caribbean, one patient from Oceania and 
two patients with unknown non-German origin were excluded.
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were grouped together with the URFs into the rare CRF/
URF subgroup.
The subtype distribution in the subset of recent infec-
tions with available CD4+ T-cell counts and viral loads 
(n = 214) was very similar to the overall study popu-
lation, with 77.1% (165/214) subtype B and 22.9% 
(49/214) non-B infections including A (4.2%, 9/214), 
C (5.1%, 11/214), D (0.9%, 2/214), F (0.9%, 3/214), G 
(2.8%, 6/214), CRF01_AE (1.9%, 4/214) and CRF02_AG 
(1.9%, 4/214) as well as 4.7% (10/214) rare CRF/URFs 
(all p values of pairwise comparisons > 0.2).
HIV-1 subtype B was associated with a significantly 
higher proportion of TDR (12.0%, 75/623) than the 
non-B subtypes (6.4%; 12/186; OR: 0.50; 95% CI: 0.27–
0.95; p = 0.04), particularly with regard to the NRTI 
mutations (5.3% in B, 1.1% in non-B, p = 0.01) (Table 2).
With regard to the main transmission groups, MSM 
were predominantly infected by subtype B, with 87.7% 
(436/497) which is significantly higher than in PWID 
(14/21) or in HET (15/65; male HET: 4/19 and female HET 
11/46; all p values MSM-PWID-HET < 0.05). In HET, sub-
type diversity was high and particularly non-B subtypes 
A (8/65), C (12/65) and G (8/65) were frequent. In PWID, 
subtype A (4/21) was the second most prevalent sub-
type (after B with 14/21), while subtypes C, D, CRF01_
AE and the group of rare CRF/URF were not identified 
in PWID. Subtype distribution in the group that did not 
report transmission type mirrored the group that did 
report transmission type (MSM + HET + PWID), with a 
slightly lower proportion of subtype B (70.5%, 155/220 
vs 79.8%, 465/583) (Figure 2A). The proportion of sub-
type non-B infections in Germans (14.0%, 68/485) was 
significantly lower than in individuals from other coun-
tries (45.6%, 72/158; p < 0.0001). Subtype B was pre-
dominant in Germans and in migrants originating from 
America and western and central Europe (417/485, 
15/17, 19/28 and 29/36, respectively). Subtype A was 
the most frequently subtype identified in eastern 
Europeans (12/27), while migrants from Africa and Asia 
were infected with a greater variety of subtypes (Figure 
2B).
For the subtypes A, B, F, CRF01_AE and the rare CRF/
URF, the main transmission route was MSM (14/41, 
436/623, 7/13, 7/16 and 14/32, respectively) while the 
subtypes C, D and G were mainly transmitted by het-
erosexual contacts (12/29, 3/6 and 8/22, respectively) 
(Figure 3A).
HIV subtype A was mostly identified in Germans (16/41) 
and eastern European patients (12/41), subtype C and 
G in Germans (12/29 and 6/22) and Africans (8/29 and 
6/22), while for Subtype D and CRF02_AG, no main ori-
gin of patients could be identified. The rare CRF/URFs 
were mainly identified in Germans (14/31) but also in 
patients originating from other continents (Europe 
(4/31), Africa (3/31), America (2/31) and Asia (1/31)) 
(Figure 3B).
A stratification according to the geographical region of 
acquisition revealed that in Germany (86.2%; 451/523), 
America (3/5) and in western (14/21) and central Europe 
(7/12), subtype B infections were mainly acquired. 
Non-B subtypes were acquired more frequently abroad 
(62.6%; 57/91) than in Germany (13.8%; 72/523; 
p < 0.05).
Discussion
We have established a molecular HIV-1 surveillance 
strategy based on samples collected in association 
with the mandatory notification system of new HIV 
diagnoses in Germany. Analysis of samples was 
restricted to recent HIV-transmissions with a defined 
duration of less than 302 days since HIV infection. This 
approach permitted us to focus on the viruses circu-
lating during any given period of time and to estimate 
current trends in the HIV epidemic, because late pre-
senters who acquired an infection before that period 
were excluded.
The overall TDR prevalence among the 2013 and 2014 
study samples was 10.8%. This is largely comparable 
to previously published cohort studies from Germany 
and several other western European countries with a 
long history of combination ART (cART) [3-5] and indi-
cates in many respects that the rate of TDR is essen-
tially stable: Patients included in the German HIV-1 
seroconverter cohort between 1996 and 2010 revealed 
TDR in 11.9% [5]. Two recent comprehensive epidemio-
logical studies involving 26 European countries carried 
Table 1
Characteristics of patients with recent infection included 
in molecular HIV surveillance, Germany, 2013–14 
(n = 809)




Not reported 5 0.6
Transmission group 
Men who have sex with men 497 61.4
Persons with heterosexual contacts 65 8.0
Persons with intravenous drug use 21 2.6
Other 6 0.7
Not reported 220 27.2
Country of origin 
Germany 485 60.0
Other 158 19.5
Not reported 166 20.5
Country of infection 
Germany 523 64.6
Other 91 11.2
Not reported 195 24.1
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out on behalf of the SPREAD-programme reported lev-
els of 8.9% (95% CI: 8.1–9.8) and 8.3% (95% CI: 7.7–
9.5) for the period from 2002 to 2007 [6] and from 2008 
to 2010, respectively [12]. Proportions of patients with 
mono-NRTI, mono-NNRTI, mono-PI, dual- and multi-
class resistance (5.0%, 2.9%, 2.5%, 0.8% and 0.4%, 
respectively) [6] were very similar to our findings (4.3%, 
2.6%, 3.0%, 0.6% and 0.2%). In both the SPREAD stud-
ies and in ours, the detected NRTI resistance mutations 
belonged to the TAM (mainly revertants of T215Y, fol-
lowed by M41L) selected by AZT and D4T. The most 
prevalent NNRTI SDRMs were K103NS, and resistance 
to PIs was mainly due to the mutations L90M and M46IL 
[6,12]. TAM are very frequent and long-term persisting 
resistance mutations [8]. De novo selection by current 
therapies is unlikely because the use of AZT and D4T 
is declining [13]. We therefore suggest that these have 
become circulating strains by onward transmission 
from untreated, and probably undiagnosed, individu-
als. While TAM may not have any particular impact on 
the success of current first-line treatments, K103N and 
K103S may still be associated with their failure [7].
Sex was not associated with TDR in our study. However, 
the prevalence of TDR was slightly but not signifi-
cantly higher among MSM, in Germans or in individu-
als infected in Germany. In studies carried out in some 
other European countries, the associations between 
TDR and MSM or subtype B (exhibiting higher TDR lev-
els) were significant [6,12,14].
HIV-1 epidemiology is characterised by compartmental-
ised subepidemics of subtypes with a dynamic nature. 
The most prevalent subtype in western European coun-
tries is subtype B, mainly as a consequence of multiple 
introductions via migration, tourism and trade from dif-
ferent geographical areas [15]. The lowest proportion 
of subtype B was reported for Portugal with 48.3% for 
patients diagnosed between 2006 and 2012 [16] while 
the highest proportion was observed in Poland with 
96.2% for patients diagnosed between 2002 and 2005 
[17].
Determinants of subtype distribution are the transmis-
sion group, country of origin and country of infection. 
Subtype B is highly prevalent in MSM, most probably 
as a result of a founder effect rather than an increased 
Table 2
Prevalence of transmitted drug resistance to the major antiretroviral drug classes in the study population stratified by 
relevant subgroups, Germany, 2013–14 (n = 809)
TDR NRTI NNRTI PI Dual Multi
n % n % n % n % n % n %
Total 87 10.8 35 4.3 21 2.6 24 3.0 5 0.6 2 0.2
Sex 
Male (n = 718) 78 10.9 32 4.5 18 2.5 21 2.9 5 0.7 2 0.3
Female (n = 68) 9 10.5 3 3.5 3 3.5 3 3.5 0 0
Not reported (n = 5) 0 0 0 0 0 0
Transmission group 
MSM (n = 497) 59 11.9 22 4.4 14 2.8 17 3.4 4 0.8 2 0.4
HET (n = 65) 4 6.2 3 4.6 1 1.5 0 0 0
PWID (n = 21) 2 9.5 1 4.8 0 1 4.8 0 0
Other (n = 6) 0 0 0 0 0 0
Not reported (n = 220) 22 10.0 9 4.1 6 2.7 6 2.7 1 0.5 0
Country of origin 
Germany (n = 485) 56 11.5 24 4.9 12 2.5 16 3.3 3 0.6 1 0.2
Other (n = 158) 12 7.6 2 1.3 5 3.2 3 1.9 1 0.6 1 0.6
Not reported (n = 166) 19 11.4 9 5.4 4 2.4 5 3.0 1 0.6 0
Country of infection 
Germany (n = 523) 63 12.0 23 4.4 15 2.9 18 3.4 5 1.0 2 0.4
Other (n = 91) 5 5.5 3 3.3 1 1.1 1 1.1 0 0
Not reported (n = 195) 19 9.7 9 4.6 5 2.6 5 2.6 0 0
HIV-1 Subtypes
B (n = 623) 75 12.0 33 5.3 16 2.6 19 3.0 5 0.8 2 0.3
Non-B (n = 186) 12 6.5 2 1.1 5 2.7 5 2.7 0 0
HET: persons with heterosexual contact; HIV: human immunodeficiency virus; MSM: men who have sex with men; NRTI: nucleotide reverse 
transcriptase inhibitors; NNRTI: non-nucleotide reverse transcriptase inhibitors; PI: protease inhibitor; PWID: people who inject drugs; TDR: 
transmitted drug resistance.
`Not reported´ data were excluded from the pairwise comparisons. All p values of pairwise comparison were > 0.05.
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transmission potential of subtype B [18]. Non-B sub-
types were significantly more frequently diagnosed in 
sub-populations originating from and often acquired 
in countries other than Germany. Most migrants with 
recent HIV infections carried subtypes dominating in 
their country of origin [19], suggesting that they may 
have acquired the infection during a visit to their home 
countries or within their community in Germany.
Interestingly, a considerable proportion of rare CRF/
URFs are present in patients originating from all conti-
nents. However, the high proportion of Germans in the 
non-B clade group, in particular those with subtype A, 
F and rare CRF/URFs, indicates that non-B strains have 
become endemic in the German population. Although 
the number of PWID analysed was low, HIV-1 subtype 
A was strikingly more common in PWID than in other 
transmission groups.
One limitation of our study was that the restriction 
to recently acquired infections over-estimates patient 
groups that are tested more frequently due to their 
awareness of transmission risks. This might explain the 
slightly higher prevalence of MSM among recent infec-
tions in our study (61.4%) compared with the notifica-
tion data for all (recent and prevalent) newly diagnosed 
HIV infections in 2013 and 2014 (57.7%) [20]. A second 
limitation was the overall genotyping success rate of 
58% in samples from recent infections. This was mainly 
due to a lack of serum spots for RNA extraction or to 
RNA degradation after inappropriate handling or ship-
ment. A technical limitation was the expected misclas-
sification of long-standing as recent infections due to a 
false recent rate (FRR) of ca 4.7% for subtype B or even 
higher for the non-B subtypes, in particular A and D 
(FRR 18.9 and 18.2%, respectively), using the BED CEIA 
assay [21]. This may have led to an over-representation 
of non-B subtypes in the study. Taking into account 
CD4+ T-cell counts and viral load data as parameters 
for recency estimation is expected to diminish this 
bias [22]. Consideration of these clinical parameters 
that were available for about one third of the samples 
only marginally reduced the prevalence for the recent 
non-B infections from 23.0% to 22.9% but, more sig-
nificantly, from 5.1% to 4.2% for subtype A, which is 
generally the most strongly affected by BED misclas-
sification. An ancillary analysis of specimens that were 
reclassified as long-standing infections based on CD4+ 
T-cell counts < 200 cells/µL and viral loads < 400 copies/
mL (n = 72) revealed 33.3% non-B and 11.1% subtype 
A (data not shown), confirming the anticipated over-
representation introduced by the BED ELISA. Based 
on these data, the lack of CD4+ T-cell counts and viral 
loads for two thirds of the sample set is estimated to 
result in an over-representation of non-B subtypes of 
less than 2.5%. Being one of two commercially avail-
able recency tests, the BED CEIA is used worldwide for 
epidemiological surveillance studies [23-28], although 
efforts to evaluate and improve serological recency 
tests are ongoing [21].
Conclusion
The TDR prevalence in recent HIV infections among 
notified newly diagnosed HIV patients in Germany was 
still high (> 10%) in 2013 and 2014 and was within the 
range of other European countries, including the pro-
portions of resistance classes. Although the selec-
tion for resistant HIV was dramatically reduced by the 
introduction of cART and new drugs [29], levels of TDR 
remain stable in all European countries and are still 
dominated by resistance to NRTI. This is most likely 
caused by a continued onward transmission of per-
sisting NRTI-resistant strains that emerged as a result 
of failed treatment regimens during the pre-cART era 
(1987–96) and not by transmission of resistant viruses 
from patients failing cART. Therefore, genotypic resist-
ance testing of HIV before first-line treatment needs to 
be continued. Since therapy-naïve and probably also 
undiagnosed patients are the predominant source of 
TDR, early detection of HIV infection followed by early 
treatment, as recommended in the current guidelines 
[7], could reduce the transmission of resistant virus 
[13,30]. Our data also demonstrate that subtype B 
remains the most frequently transmitted subtype in 
Germany because of its high prevalence in MSM.
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